BURNABY, BC, Jan. 19, 2012 /CNW/ - Innovative Targeting Solutions Inc. (ITS), the developer of the next generation fully human antibody technology (HuTARG), today announced the initiation of a research collaboration with Amgen Inc. (Thousand Oaks, CA). The agreement will allow Amgen to assess ITS's HuTARG technology for a broader potential collaboration in the future.
About Innovative Targeting Solutions Inc.
Founded in 2008, Innovative Targeting Solutions Inc. is a privately-held company that has developed a next generation platform for the generation of fully human antibody therapeutics using its proprietary HuTARG technology. The HuTARG technology is a fully mammalian technology that generates antibody diversity in vitro via RAG1/RAG2 mediated V(D)J recombination. For more information, visit www.innovativetargeting.com
For further information:
For more information, visit www.innovativetargeting.com